T Cell Receptors Targeting HPV 6 or HPV 11
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens.
Use of Acetalax for Treatment of Triple Negative Breast Cancer
Summary:
NCI seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate).
Pyruvate Kinase M2 Activators for the Treatment of Cancer
NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics.
Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia
NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics.
MUP-tTA Mouse Model for Liver Function Studies
Tetracycline-responsive transcriptional activator driven by the liver-specific mouse major urinary protein promoter (MUP-tTA).
Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies
Tetracycline-responsive transcriptional activator driven by the liver-specific mouse albumin promoter (Alb-tTA).
Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus
The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that will likely change the HCV treatment paradigm. However, the effectiveness of these new drugs can vary depending on the HCV genotype. Thus, there is still the need for additional new therapeutics against HCV.
Bifunctional Antibody Fusion Molecules for Use in Cancer Immunotherapy
Summary:
The National Cancer Institute is seeking research co-development partners and licensing collaborators to accelerate the development and commercialization of innovative bifunctional antibody fusion molecules designed to activate and expand engineered TCR-expressing cells, advancing next-generation cancer immunotherapies.
Clinical Advancements in Intracellular Pathogen Infection Treatment through CD47 Blockade for Augmented Phagocytic Clearance
The technology described involves a groundbreaking method for treating intracellular pathogen infections by targeting CD47, a widely expressed transmembrane glycoprotein that acts as a ligand for phagocytic receptors. By administering agents that inhibit CD47 binding to these receptors, the approach enhances the phagocytic removal of infected cells, leading to increased clearance of intracellular pathogens.
Extended Serum Half-Life in Therapeutic Antibodies: Advancements with Enhanced lgG1 Fe Variants
This technology involves the development of lgG1 Fe variants designed to interact more effectively with the neonatal Fc receptor (FcRn) in a pH-dependent manner. By enhancing this interaction, these variants extend the serum half-life of therapeutic antibodies, reducing the need for frequent administration. This breakthrough holds the potential to make therapeutic antibody treatments more convenient, cost-effective, and accessible for a wide range of diseases.